modelD08AC02
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Chlorhexidine | |
| ATC code: | D08AC02 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 7.2 | L |
| clearance: | 0.283 | L/min |
| other parameters in model implementation | ||
Chlorhexidine is a broad-spectrum antiseptic and disinfectant that is used to reduce bacteria on the skin and mucous membranes. It is commonly used for skin disinfection before surgery, wound cleaning, and as a mouthwash for oral hygiene. Chlorhexidine is approved and widely used in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters for chlorhexidine following oral administration in healthy adult volunteers (sex not specified; typical mucosal/skin and oral use).
References
Toljanic, JA, et al., & Shapiro, RD (1992). Evaluation of the substantivity of a chlorhexidine oral rinse in irradiated head and neck cancer patients. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 50(10) 1055–1059. DOI:10.1016/0278-2391(92)90490-q PUBMED:https://pubmed.ncbi.nlm.nih.gov/1527659
Lim, SY, et al., & Heard, CM (2020). Mucoadhesive thin films for the simultaneous delivery of microbicide and anti-inflammatory drugs in the treatment of periodontal diseases. International journal of pharmaceutics 573 118860–None. DOI:10.1016/j.ijpharm.2019.118860 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31759104
Salmanli, M, et al., & Tuzuner, T (2021). Investigation of the antimicrobial activities of various antimicrobial agents on Streptococcus Mutans Sortase A through computer-aided drug design (CADD) approaches. Computer methods and programs in biomedicine 212 106454–None. DOI:10.1016/j.cmpb.2021.106454 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34656905
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)